Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)

A Phase III Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ in Healthy Adults in India

This study will determine if ZOSTAVAX™ is safe, tolerable, and immunogenic in healthy adults in India.

Inclusion Criteria:

• No fever on day of vaccination
• Females have a negative pregnancy test and use an acceptable method of birth control, or are postmenopausal
• Underlying chronic illnesses must be stable

Exclusion Criteria:

• History of hypersensitivity reaction to any vaccine component
• Prior receipt of a varicella or zoster vaccine
• Prior history of herpes zoster
• Have recently had another vaccination
• Have recently received blood products other than autologous blood transfusion
• Pregnant or breast feeding
• Use of immunosuppressive therapy
• Known or suspected immune dysfunction
• Use of nontopical antiviral therapy with activity against herpesvirus